Adult T-cell leukemia-lymphoma (ATLL) is an aggressive leukemia of T lymphocytes caused by human T-cell leukemia virus type I. The disease is endemic in southwestern Japan, the Caribbean, Central and South America, Central and South Africa, Melanesia, Aboriginal Australia and the Middle East. ATLL is highly resistant to existing treatments. Almost all ATLL patients die within a year of diagnosis. There is a clear and urgent need for new ATLL treatments.

Leukemia Therapeutics is committed to develop targeted therapies for ATLL that will improve patient survival. Specifically, our proprietary discovery platform has identified five new therapeutic targets on the surface of ATLL. We are currently developing antibodies that bind these targets and testing their therapeutic efficacy.